source
- FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancerRevolution Medicines received FDA approval for its oral RAS inhibitor daraxonrasib, branded as Rasonque, to treat patients with metastatic pancreatic adenocarcinoma who have already received prior…
- FDA grants early approval to RevMed's pancreatic cancer drug RasonqueFDA granted early approval to Revolution Medicines' daraxonrasib, now named Rasonque, for pancreatic adenocarcinoma, arriving 6.5 months before the FDA deadline. The oral RAS inhibitor demonstrate…